Rituximab in the treatment of Graves’ orbitopathy: latest updates and perspectives

Abstract

Graves’ orbitopathy (GO) is a potentially sight-threatening and disfiguring, extrathyroidal manifestation of Graves’ disease. It often impairs patients’ qu ality of life, causing severe social and psychological sequelae. Intravenous glucocorticosteroids is currently the mainstay of therapy, but the efficacy is often underwhelming and recurrence rate is high. For many years, clinicians have been searching for new methods of treatment. Rituximab (RTX) is a chimeric monoclonal antibody targeted against CD20 w hich is a surface antigen present on B cells. It is frequently used to treat non-Hodgkin’ s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, or various types of vasculitis. Numerous clinical trials employing RTX in the treatment of GO have shown promising results. RTX is currently considered to be a valid second-line treatment option in patients unresponsive to previous interventions or in disease reactivation. This revi ew summarizes the available literature on this topic, including two largest, randomized, co ntrolled studies. Potential benefits, as well as the limitations of RTX therapy, are discuss ed.

Keywords

• graves’ orbitopathy
• rituximab
• thyroid eye disease
• graves’ disease